HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) TCRT, a leader in T cell receptor (TCR) cell therapy advancing a pipeline of clinical-stage therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, chief scientific officer of a stealth early-stage biotechnology company. to the Management Board of the company with immediate effect. dr Hofmeister becomes Dr. Replace Chris Bowden.

“We thank Chris for his invaluable contributions to Alaunos during his tenure and welcome Robert to the Alaunos board,” said Kevin S. Boyle, Sr., Alaunos Chief Executive Officer. “Robert brings deep expertise in the discovery and development of engineered T cell receptor therapies and a background in cellular immunology and translational science. We look forward to using his insights and experience to accelerate the expansion of our library of TCRs and advance our TCR-T Library Phase 1/2 study.”

Before joining his current company, Dr. Hofmeister has worked in scientific management at TCR for almost seven years² Therapeutics, a company developing novel therapies utilizing the TCR complex to target both solid tumors and hematologic malignancies, and culminated in the role of Chief Scientific Officer. As the first TCR² As an employee, he was instrumental in establishing and leading the R&D function and driving the development of the proprietary TRuC^®-T cell platform and its TC-210 program from concept to first approved Investigational New Drug (IND) application. As part of the executive leadership team, he also helped successfully take the company public and secure growth capital.

“Alaunos is at the forefront of science and development of T-cell therapies, an exciting area that I am passionate about and have worked in for decades,” said Dr. Hofmeister. “With proprietary platforms, an industry-leading library of TCRs, and the first TCR-T clinical trial in solid tumors…